The International Online Journal of Cancer & Therapeutics is a peer-reviewed open acess journal that publishes original research articles as well as review articles in all areas of Oncology. this practical journal also includes information on new products, new therapies and patient management, as well as reviews of the latest research. Cancer is a complex problem. The international effort to understand and control it involves clinicians trained in many branches of medicine and scientists from most biological disciplines, chemistry, pharmaceutical and physical sciences The International Online Journal of Cancer & Therapeutics exists to serve the needs of this diverse community, providing a forum for prompt communication of original and innovative research findings that have relevance to understanding the etiology of cancer and to improving the treatment and survival of patients.

The journal publishes important original studies, reviews, and perspectives within the major topic areas of biology of premalignancy, risk factors and risk assessment, early detection research, immunoprevention, and chemopreventive and other interventions, including the basic science behind them. This journal comprises preclinical, clinical and translational research, with special attention given to molecular discoveries and an emphasis on building a translational bridge between the basic and clinical sciences. Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting.

Oncology is the diagnosis and treatment of cancers,including breast,prostate,colon,lung and ovarian cancers as well as brain tumors,leukemia,lymphoma and many other types of cancer.. A doctor who works in the field of oncology is called an oncologist. The primary regions of oncology are radiation, which is worried with radiation treatment, or radiotherapy; surgical, which is contained specialists who spend significant time in tumor evacuation; therapeutic, which manages disease drugs, including chemotherapy; and interventional, which includes interventional radiologists who have some expertise in insignificantly obtrusive picture guided tumor treatment.


committee

Members

ThumbnailImage

Shinjini Singh

Research Scientist

Shinjini Singh currently works at the Clinical Trials Center, Seidman Cancer Center, Cleveland Medical Center, University Hospitals, Cleveland, Ohio and previously worked as a Research Scientist in the Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, Texas. She received her Ph.D. degree from the Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. Her past research experience of about 7 years includes the study of parallel analysis including gene expression arrays, protein expression arrays and tissue arrays to refine the cancer diagnosis. Her broad range of experience also includes molecular biology techniques that can be harnessed for practical applications like caner diagnostics and therapeutics. She has published many research papers in peer-reviewed journals and book chapters in with world-renowned publishers like Springer production and Bentham Sciences. She has the ultimate accolades of being honorary editorial board member and reviewer in a number of highly reputed international cancer/life science journals.

  • Association for Women in Science (AWIS); Gulf Coast Houston
  • American Society of Clinical Oncology (ASCO)
  • Shinjini Singh, “Cancer, a Multigenic Disease Requires Nature Derived Multi-targeted Drugs”, Advances in Cancer Prevention, 1(4), Sep 2016, p. 1-2. (Short Commentary)
  • Shinjini Singh and Mritunjai Singh, “Paget’s Disease of Breast”, Hereditary Genetics: Current Research, 5(1), Apr 2016, p. 1000i102. (Short Commentary)
  • Sahdeo Prasad, Lokesh Deb, Amit K. Tyagi, Jiamin Huang, Qaisar Manzoor, Arfaa Sajid, Shinjini Singh, Sasha Raman, and Bharat B. Aggarwal. “FDA Approved Anticancer Drugs from Mother Nature: Past, Present and Future”, Biotech Journal. (Communicated)
  • Singh Shinjini, Rajput Sandeep, Singh Mritunjai, Misra Pravas, Mohan Gyanendra, Kumar Mohan, Singh Rakesh,Gambhir Indrajeet. “p53 gene: mutation and immunohistochemical analysis in patients with invasive ductal carcinoma of breast”, American Journal of Biochemistry and Biotechnology, 9(4), Aug. 2013, p. 398-406.
  • Sushma Tiwari, Shinjini Singh, Kishor Patwardhan, Sangeeta Gehlot, I.S. Gambhir, “Effect of Centella Asiatica on Mild Cognitive Impairment (MCI) and other common age- related clinical problems”, Digest Journal of Nanomaterials and Biostructures, Vol. 3, No. 4, Dec. 2008, p. 215-220.
  • Mritunjai Singh, Shinjini Singh, S. Prasad, I. S. Gambhir, “Nanotechnology in Medicine and Antibacterial Effect of Silver Nanoparticles”, Digest Journal of Nanomaterials and Biostructures, Vol. 3, No. 3, Sep. 2008, p. 115-122.
  • Shinjini Singh, Mritunjai Singh, I.S. Gambhir, “Nanotechnology for Alzheimer’s Disease Detection”, Digest Journal of Nanomaterials and Biostructures, Vol.3, No.2, June 2008, p. 75-79.
  • Shinjini Singh, S Prasad, I.S. Gambhir. “Biomarkers in the diagnosis of dementia of Alzheimer’s type (DAT)”. Indian Journal of Geriatric Mental Health, Vol. 3, No. 1, Nov. 2007, p. 18-30.